Albumin and its application in drug delivery (Q38292087)

1 September 2017

1 reference

title

Albumin and its application in drug delivery (English)

1 reference

1 September 2017

1 reference

Darrell Sleep

1

1 reference

PubMed ID

25518870

1 September 2017

language of work or name

English

0 references

publication date

18 December 2014

1 reference

Expert Opinion on Drug Delivery

1 September 2017

1 reference

1 September 2017

12

1 reference

1 September 2017

5

1 reference

1 September 2017

793-812

1 reference

Perspective-- FcRn transports albumin: relevance to immunology and medicine

1 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Albumin as a versatile platform for drug half-life extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Human serum albumin: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Structural basis of the drug-binding specificity of human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Investigation of an albumin-enriched fraction of human serum and its albuminome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

The extraordinary ligand binding properties of human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Albumin-drug interaction and its clinical implication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Novel insights into the pleiotropic effects of human serum albumin in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Ligand binding strategies of human serum albumin: how can the cargo be utilized?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Binding of transition metal ions to albumin: sites, affinities and rates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Role of Tyr84 in controlling the reactivity of Cys34 of human albumin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Albumin as a nitric oxide-traffic protein: characterization, biochemistry and possible future therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

NMR reveals molecular interactions and dynamics of fatty acid binding to albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Fatty acid binding to serum albumin: molecular simulation approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Unraveling the mysteries of serum albumin-more than just a serum protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Albumin-bound paclitaxel: a next-generation taxane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Cubilin is essential for albumin reabsorption in the renal proximal tubule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Molecular mechanisms of receptor-mediated endocytosis in the renal proximal tubular epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

FcRn: the neonatal Fc receptor comes of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Neonatal Fc receptor: from immunity to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Clinical ramifications of the MHC family Fc receptor FcRn

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Albumin binding to FcRn: distinct from the FcRn-IgG interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

The immunologic functions of the neonatal Fc receptor for IgG

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

An Fc receptor structurally related to MHC class I antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Expression and crystallization of a soluble and functional form of an Fc receptor related to class I histocompatibility molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Familial hypercatabolic hypoproteinemia. A disorder of endogenous catabolism of albumin and immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Crystal structure of an HSA/FcRn complex reveals recycling by competitive mimicry of HSA ligands at a pH-dependent hydrophobic interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Dissection of the neonatal Fc receptor (FcRn)-albumin interface using mutagenesis and anti-FcRn albumin-blocking antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Human serum albumin isoforms: genetic and molecular aspects and functional consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Mutations and polymorphisms of the gene of the major human blood protein, serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Antibodies against gluco-oxidatively modified human serum albumin detected in diabetes-associated complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Human serum albumin from recombinant DNA technology: challenges and strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Summary of recombinant human serum albumin development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Structure, properties, and engineering of the major zinc binding site on human albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

O2 and CO binding properties of artificial hemoproteins formed by complexing iron protoporphyrin IX with human serum albumin mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Oxidation of Arg-410 promotes the elimination of human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Impact of albumin on drug delivery--new applications on the horizon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Clinical impact of serum proteins on drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

New strategy for the extension of the serum half-life of antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Insulin detemir: from concept to clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Insulin degludec: overview of a novel ultra long-acting basal insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

An overview of the pharmacokinetics, efficacy and safety of liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Review of the therapeutic uses of liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Engineering of a femtomolar affinity binding protein to human serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

The albumin-binding domain as a scaffold for protein engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Bicyclization and tethering to albumin yields long-acting peptide antagonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Albumin binding as a general strategy for improving the pharmacokinetics of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Adnectins: engineered target-binding protein therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Novel exenatide analogs with peptidic albumin binding domains: potent anti-diabetic agents with extended duration of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Prolonged circulation of recombinant human granulocyte-colony stimulating factor by covalent linkage to albumin through a heterobifunctional polyethylene glycol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Kringle 5 peptide-albumin conjugates with anti-migratory activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Albumin-conjugated C34 peptide HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCID-hu Thy/Liv mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Synthesis and evaluation of insulin-human serum albumin conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Site specific 1:1 opioid:albumin conjugate with in vitro activity and long in vivo duration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Preparation and characterization of albumin conjugates of a truncated peptide YY analogue for half-life extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Identification of CJC-1131-albumin bioconjugate as a stable and bioactive GLP-1(7-36) analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Native albumin for targeted drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Proteins: emerging carrier for delivery of cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

A clinical update of using albumin as a drug vehicle - a commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Pharmacokinetics of 5-Aminofluorescein-Albumin, a Novel Fluorescence Marker of Brain Tumors During Surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Poly-s-nitrosated albumin as a safe and effective multifunctional antitumor agent: characterization, biochemistry and possible future therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Synthesis, cleavage profile, and antitumor efficacy of an albumin-binding prodrug of methotrexate that is cleaved by plasmin and cathepsin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Targeted drug delivery by in vivo coupling to endogenous albumin: an albumin-binding prodrug of methotrexate (MTX) is better than MTX in the treatment of murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Paclitaxel and its formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Treatment innovations for metastatic breast cancer: nanoparticle albumin-bound (NAB) technology targeted to tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Nab-paclitaxel for metastatic pancreatic cancer: clinical outcomes and potential mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Safety and efficacy evaluation of albumin-bound paclitaxel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Challenges in development of nanoparticle-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Lactosaminated human albumin, a hepatotropic carrier of drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

RGD-conjugated albumin nanoparticles as a novel delivery vehicle in pancreatic cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Efficient mucosal vaccination mediated by the neonatal Fc receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

Orthogonal Assembly of a Designed Ankyrin Repeat Protein–Cytotoxin Conjugate with a Clickable Serum Albumin Module for Half-Life Extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425247.2015.993313

10.1517/17425247.2015.993313

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference

PubMed ID

25518870